bone neoplasms

Summary

Summary: Tumors or cancer located in bone tissue or specific BONES.

Top Publications

  1. Barthel S, Hays D, Yazawa E, Opperman M, Walley K, Nimrichter L, et al. Definition of molecular determinants of prostate cancer cell bone extravasation. Cancer Res. 2013;73:942-52 pubmed publisher
  2. Hashisako M, Wakamatsu K, Ikegame S, Kumazoe H, Nagata N, Kajiki A. Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. Tohoku J Exp Med. 2012;228:163-8 pubmed
    ..When determining the efficacy of treatments that target carcinomas with bone metastases, it is important to note that flare phenomenon is often indistinguishable from disease progression indicators...
  3. Chen J, Fong Y, Tang C. Novel strategies for the treatment of chondrosarcomas: targeting integrins. Biomed Res Int. 2013;2013:396839 pubmed publisher
    ..Finally, novel therapeutic strategies for targeting these molecules will be discussed. ..
  4. Cai C, Zhao G, Tian L, Liu L, Yan K, Ma Y, et al. miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep. 2012;28:1764-70 pubmed publisher
    ..The data presented here demonstrate that the CCND1 contributes to osteosarcoma cell proliferation, suggesting that repression of CCND1 by miR-15a and miR-16-1 could be used for osteosarcoma therapy...
  5. Gill J, Ahluwalia M, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137:89-99 pubmed publisher
    ..This manuscript will review the rationale for conventional chemotherapy used in the treatment of osteosarcoma, as well as agents in varying stages of development that may have promise for treatment in the future...
  6. Li B, Yang Y, Jiang S, Ni B, Chen K, Jiang L. Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. Int J Oncol. 2012;41:1809-19 pubmed publisher
  7. Kim H, Lee S, Kim Y, Park J, Lee K, Yoo Y, et al. Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells. Int J Oncol. 2013;42:1985-92 pubmed publisher
    ..Therefore, it is suggested that combination treatment involving low-dose PCX therapy and autophagy inhibitor therapy could be an effective and potent strategy for improved chemotherapy for OS in the near future...
  8. Antonarakis E, Heath E, Posadas E, Yu E, Harrison M, Bruce J, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;71:883-92 pubmed publisher
    ..Because a C max of ?142 ng/mL is required for tubulin polymerization inhibition (defined from preclinical studies), higher once-daily dosing will be used in future trials. ..
  9. Owen S, Ye L, Sanders A, Mason M, Jiang W. Expression profile of receptor activator of nuclear-?B (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res. 2013;33:199-206 pubmed
    ..These molecules have been implicated in bone metastasis. Since the discovery of the triad of RANK, RANKL and OPG in healthy bone turnover, a better understanding of these factors in bone metastasis has been sought...

More Information

Publications62

  1. Brady D, Parker C, O Sullivan J. Bone-targeting radiopharmaceuticals including radium-223. Cancer J. 2013;19:71-8 pubmed publisher
  2. Richter G, Fasan A, Hauer K, Grunewald T, Berns C, Rössler S, et al. G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1. J Pathol. 2013;230:70-81 pubmed publisher
    ..Thus, GPR64 expression in ES maintains an immature phenotype that is less sensitive to TRAIL-induced apoptosis and via its up-regulation of PGF and MMP1 orchestrates and promotes invasiveness and metastatic spread...
  3. Wong K, Kumta S. Computer-assisted tumor surgery in malignant bone tumors. Clin Orthop Relat Res. 2013;471:750-61 pubmed publisher
    ..Small recent case series using CT-based navigation suggest such approaches may aid in surgical planning and improve accuracy of intended resections, but the accuracy and clinical use have not been confirmed...
  4. Carrasquillo J, O Donoghue J, Pandit Taskar N, Humm J, Rathkopf D, Slovin S, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1384-93 pubmed publisher
    ..We conducted a study to better profile the pharmacokinetics, pharmacodynamics, and biodistribution of this agent...
  5. Parker C, Nilsson S, Heinrich D, Helle S, O Sullivan J, Fossa S, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-23 pubmed publisher
    ..We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases...
  6. Zhao H, Ma B, Wang Y, Han T, Zheng L, Sun C, et al. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncol Rep. 2013;29:1027-36 pubmed publisher
    ..Therefore, it can be concluded that through the inhibition of CD44 expression levels, miR-34a plays a significant role in the migration and invasion of osteosarcoma cells...
  7. Ma Y, Ren Y, Han E, Li H, Chen D, Jacobs J, et al. Inhibition of the Wnt-?-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun. 2013;431:274-9 pubmed publisher
    ..Our findings provide some novel insight to OS pathogenesis and lay a foundation for future application of Wnt-?-catenin and Notch inhibitors together with the currently used chemotherapeutic drugs to improve the outcome of OS treatment...
  8. Tzeng H, Tsai C, Chang Z, Su C, Wang S, Hwang W, et al. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol. 2013;85:531-40 pubmed publisher
    ..Taken together, these results indicate that IL-6 occurs through ASK1 and p38, which in turn activates AP-1, resulting in the activations of VEGF expression and contributing the angiogenesis of human osteosarcoma cells...
  9. Canon J, Bryant R, Roudier M, Branstetter D, Dougall W. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat. 2012;135:771-80 pubmed publisher
  10. Ford J, Jones R, Elders A, Mulatero C, Royle P, Sharma P, et al. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer. 2013;49:416-30 pubmed publisher
    ..To evaluate the evidence for denosumab for the treatment of bone metastases secondary to solid tumours and, using a network meta-analysis, indirectly compare denosumab with bisphosphonates and best supportive care...
  11. Jansen J, van de Sande M, Dijkstra P. Poor long-term clinical results of saddle prosthesis after resection of periacetabular tumors. Clin Orthop Relat Res. 2013;471:324-31 pubmed publisher
    ..The long-term survival of these reconstructions is unclear...
  12. Li Z. Potential of human ?? T cells for immunotherapy of osteosarcoma. Mol Biol Rep. 2013;40:427-37 pubmed publisher
    ..More importantly, we discuss potential strategies of the combination of expanded ?? T cells and bisphosphonates, and modification and expansion of ?? TCR modified ?? T cells for improving its efficacy for the treatment of osteosarcoma...
  13. Namløs H, Meza Zepeda L, Barøy T, Østensen I, Kresse S, Kuijjer M, et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS ONE. 2012;7:e48086 pubmed publisher
    ..In order to investigate the involvement of miRNAs in osteosarcoma development, global microarray analyses of a panel of 19 human osteosarcoma cell lines was performed...
  14. Bertucci F, Araujo J, Giovannini M. Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. Scand J Gastroenterol. 2013;48:4-8 pubmed publisher
    ..Pancreatic metastasis from osteosarcoma and Ewing sarcoma is extremely rare. Differential diagnosis with primary pancreatic carcinoma is crucial before any treatment, but may be very difficult...
  15. Biermann J, Adkins D, Agulnik M, Benjamin R, Brigman B, Butrynski J, et al. Bone cancer. J Natl Compr Canc Netw. 2013;11:688-723 pubmed
    ..These guidelines discuss the management of chordoma, giant cell tumor of the bone, and osteosarcoma...
  16. Smith D, Smith M, Sweeney C, Elfiky A, Logothetis C, Corn P, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412-9 pubmed publisher
    ..We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort...
  17. Vashisht S, Bagler G. An approach for the identification of targets specific to bone metastasis using cancer genes interactome and gene ontology analysis. PLoS ONE. 2012;7:e49401 pubmed publisher
    ..Specifically, our study provides a set of potential targets that are of ontological and regulatory relevance to secondary bone cancer...
  18. Hagiwara M, Delea T, Saville M, Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16:23-7 pubmed publisher
    ..The objective of this study was to document current patterns of healthcare utilization and costs of SREs in patients with prostate cancer and bone metastases...
  19. Muralidharan A, Wyse B, Smith M. Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacol Biochem Behav. 2013;106:33-46 pubmed publisher
  20. van Oosterwijk J, de Jong D, van Ruler M, Hogendoorn P, Dijkstra P, van Rijswijk C, et al. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. BMC Cancer. 2012;12:375 pubmed publisher
    ..In pre-clinical research aiming at the identification of novel treatment targets, the need for representative cell lines and model systems is high, but availability is scarce...
  21. Moses J, Gibson N, Plesec T, PLAUTZ G, Kay M, Soldes O. Metastatic osteosarcoma to the stomach and ascending colon in a pediatric patient causing gastrointestinal hemorrhage. J Pediatr Surg. 2013;48:e1-3 pubmed publisher
    ..The patient is free of recurrent hemorrhage at 24months after metastectomy. Resection of gastrointestinal metastases of osteosarcoma offers good palliation of chronic hemorrhage related to these lesions...
  22. Casimiro S, Mohammad K, Pires R, Tato Costa J, Alho I, Teixeira R, et al. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS ONE. 2013;8:e63153 pubmed publisher
    ..Therefore, RANKL inhibition in bone metastatic disease may decrease the levels of the osteoclastogenesis inducer MMP-1, contributing to a better clinical outcome...
  23. Al Nammari S, Danesh A, Mussa M, Al Hadithy N. The portrayal of bone tumours in the press. Musculoskelet Surg. 2013;97:21-3 pubmed publisher
    ..001 Chi-squared test)-and there was a trend for them to be more factually correct overall-68 versus 50% (p = 0.192 Fisher's exact Test)...
  24. Posthumadeboer J, van Egmond P, Helder M, de Menezes R, Cleton Jansen A, Belien J, et al. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget. 2012;3:1169-81 pubmed
    ..Collectively, JIP1 appears a clinically relevant novel target in OS to enhance the efficacy of doxorubicin treatment by means of RNA interference or pharmacological inhibition...
  25. Planas Morin J, Morote Robles J. Skeletal complications of ADT: disease burden and treatment options. Asian J Androl. 2012;14:670-5 pubmed publisher
  26. Durnali A, Alkis N, Cangur S, Yükrük F, Inal A, Tokluoglu S, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624 pubmed publisher
    ..002) and the presence of metastasis at diagnosis (p = 0.011) were associated with poor OS, whereas the patients who received chemotherapy for recurrent disease had a longer OS (p = 0.009)...
  27. Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Yardley D, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082-92 pubmed publisher
    ..This pre-planned analysis evaluates the efficacy and safety of denosumab versus zoledronic acid across three pivotal studies...
  28. Park J, Song K, O J, Kim W, Choi M, Park C. Bone recurrence after curative resection of gastric cancer. Gastric Cancer. 2013;16:362-9 pubmed publisher
    ..The aim of this study was to investigate the incidence of and related risk factors for bone recurrence after surgical resection of gastric cancer...
  29. Song L, Yang J, Duan P, Xu J, Luo X, Luo F, et al. MicroRNA-24 inhibits osteosarcoma cell proliferation both in vitro and in vivo by targeting LPAAT?. Arch Biochem Biophys. 2013;535:128-35 pubmed publisher
    ..In conclusion, our study indicates that miR-24 is reduced in osteosarcoma cells, contributing to up-regulation of LPAAT? and resultant osteosarcoma cell proliferation...
  30. Wu M, Chen L, Hsu H, Lin J, Lin Y, Tsai F, et al. Endothelin-1 enhances cell migration through COX-2 up-regulation in human chondrosarcoma. Biochim Biophys Acta. 2013;1830:3355-64 pubmed publisher
    ..The effect of endothelin-1 (ET-1) on migration activity in human chondrosarcoma cells is not clearly understood. Here, we found that ET-1 increased the migration and expression of cyclooxygenase (COX)-2 in human chondrosarcoma cells...
  31. Deng Z, Niu G, Cai L, Wei R, Zhao X. The prognostic significance of CD44V6, CDH11, and ?-catenin expression in patients with osteosarcoma. Biomed Res Int. 2013;2013:496193 pubmed publisher
    ..Thus, our results indicated abnormal expression of CD44V6, CDH11, and ?-catenin in osteosarcomas and osteochondromas, which may provide important indicators for further research...
  32. Lipton A, Cook R, Brown J, Body J, Smith M, Coleman R. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses. Clin Oncol (R Coll Radiol). 2013;25:217-26 pubmed publisher
    ..However, the disease course has not been well characterised in patients with bone metastases but normal NTX levels. Therefore, the aim of this study was to evaluate the patterns of skeletal morbidity in patients with normal NTX levels...
  33. Saylor P, Armstrong A, Fizazi K, Freedland S, Saad F, Smith M, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013;63:309-20 pubmed publisher
    ..Bone metastases are a common feature of advanced genitourinary malignancies and a prominent cause of morbidity and mortality...
  34. Scagliotti G, Hirsh V, Siena S, Henry D, Woll P, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7:1823-1829 pubmed publisher
    ..7% denosumab versus 0.8% ZA). Hypocalcemia rates were 8.6% with denosumab and 3.8% with ZA. In this exploratory analysis, denosumab was associated with improved overall survival compared with ZA, in patients with metastatic lung cancer. ..
  35. Paller C, Carducci M, Philips G. Management of bone metastases in refractory prostate cancer--role of denosumab. Clin Interv Aging. 2012;7:363-72 pubmed publisher
    ..The role of denosumab in prostate cancer will continue to evolve either as monotherapy or in combination with other bone-targeting strategies...
  36. Wong K, Kumta S. Joint-preserving tumor resection and reconstruction using image-guided computer navigation. Clin Orthop Relat Res. 2013;471:762-73 pubmed publisher
    ..Further, the tumor margin on preoperative CT and/or MR images is difficult to transpose to the actual extent of tumor in the bone in the operating room...
  37. Peddi P, Lopez Olivo M, Pratt G, Suarez Almazor M. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39:97-104 pubmed publisher
    ..We conducted a systematic review of the literature to determine the efficacy and safety of denosumab in reducing skeletal-related events (SRE) in patients with bone metastases...
  38. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, O Sullivan J, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738-46 pubmed publisher
    ..We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases...
  39. Kresse S, Rydbeck H, Skårn M, Namløs H, Barragan Polania A, Cleton Jansen A, et al. Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS ONE. 2012;7:e48262 pubmed publisher
    ..We have integrated genome-wide genetic and epigenetic profiles from the EuroBoNeT panel of 19 human osteosarcoma cell lines based on microarray technologies...
  40. Behjati S, Tarpey P, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479-82 pubmed publisher
    ..Gly34Val alterations in childhood brain tumors, a remarkable picture of tumor type specificity for histone H3.3 driver alterations emerges, indicating that histone H3.3 residues, mutations and genes have distinct functions. ..
  41. Lucero C, Vega O, Osorio M, Tapia J, Antonelli M, Stein G, et al. The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol. 2013;228:714-23 pubmed publisher
    ..Thus, regulatory mechanisms controlling Runx2 expression in osteosarcoma cells must balance Runx2 protein levels to promote its putative oncogenic functions, while avoiding suppression of bone tumor growth...
  42. Mottard S, Grimer R, Abudu A, Carter S, Tillman R, Jeys L, et al. Biological reconstruction after excision, irradiation and reimplantation of diaphyseal tibial tumours using an ipsilateral vascularised fibular graft. J Bone Joint Surg Br. 2012;94:1282-7 pubmed publisher
    ..We believe this to be a satisfactory method of biological reconstruction of the tibial diaphysis in selected patients...
  43. Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012;18:4841-9 pubmed
    ..We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL)...
  44. van der Heijden L, van de Sande M, Dijkstra P. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones. Acta Orthop. 2012;83:401-5 pubmed publisher
    ..The aim of the study was the identification of individual risk factors after curettage with adjuvants in GCTB...
  45. Exposito J, Jaén J, Alonso E, Tovar I. Use of palliative radiotherapy in brain and bone metastases (VARA II study). Radiat Oncol. 2012;7:131 pubmed publisher
    ..The objective of this study was to analyze the variability of RT utilization rates in clinical practice and the accessibility to medical technology in our region...
  46. Wong K, Kumta S, Sze K, Wong C. Use of a patient-specific CAD/CAM surgical jig in extremity bone tumor resection and custom prosthetic reconstruction. Comput Aided Surg. 2012;17:284-93 pubmed publisher
    ..Further assessment in a larger population is necessary to determine the clinical efficacy of the technique...
  47. Parker C, Pascoe S, Chodacki A, O Sullivan J, Germa J, O Bryan Tear C, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189-97 pubmed publisher
    ..Patients with castration-resistant prostate cancer (CRPC) and bone metastases have an unmet clinical need for effective treatments that improve quality of life and survival with a favorable safety profile...
  48. Mohseny A, Cai Y, Kuijjer M, Xiao W, van den Akker B, de Andrea C, et al. The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. Eur J Cancer. 2012;48:3429-38 pubmed publisher
    ..This may imply that drugs restoring impaired signalling pathways in osteosarcoma might change the tumour's aggressive clinical course, however targeted pathway modulation in vitro did not affect cell proliferation...
  49. Cates J. Pathologic fracture a poor prognostic factor in osteosarcoma: Misleading conclusions from meta-analyses?. Eur J Surg Oncol. 2016;42:883-8 pubmed publisher
    ..Analysis of individual patient data, which would require collaboration among different groups, would circumvent this limitation of meta-analysis. ..
  50. Svejda B, Muschitz C, Gruber R, Brandtner C, Svejda C, Gasser R, et al. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Wien Med Wochenschr. 2016;166:68-74 pubmed publisher
    ..This requires a close teamwork for the treating physician and the dentist. It is necessary that this information is disseminated to other relevant health care professionals and organizations. ..
  51. Chun Y, Rhyu K, Cho K, Cho Y, Lee C, Han C. Osteochondroma Arising from Anterior Inferior Iliac Spine as a Cause of Snapping Hip. Clin Orthop Surg. 2016;8:123-6 pubmed publisher
    ..This rare case of snapping hip syndrome from the AIIS was treated surgically and the symptoms completely disappeared after excision of the tumor. ..
  52. Liang W, Yang C, Peng J, Qian Y, Wang Z. The Expression of HSPD1, SCUBE3, CXCL14 and Its Relations with the Prognosis in Osteosarcoma. Cell Biochem Biophys. 2015;73:763-8 pubmed publisher
    ..Targeted inhibition of these three genes could inhibit the proliferation of the tumor, which may become a new therapeutic target. ..
  53. Li J, Wang Z, Ji C, Chen G, Liu D, Zhu H. What are the Oncologic and Functional Outcomes After Joint Salvage Resections for Juxtaarticular Osteosarcoma About the Knee?. Clin Orthop Relat Res. 2017;475:2095-2104 pubmed publisher
    ..Level IV, therapeutic study. ..